The global race to develop so-called “double G” and “triple G” agonists is heating up to boost the efficacy of…
REGULATORY
Govt’s Council Calls for Pushing Drug Innovation, Generic Revamp
The Japanese government’s advisory panel on October 30 unveiled a list of priority policy measures to be incorporated in a new economic package expected to be complied as early as next month. The list embraced a call for capital investments…
To read the full story
Related Article
- PM Ishiba Takes Note of Opposition Party’s Plea for Scrapping Off-Year Revisions
December 9, 2024
- Japan Needs Transparent Debates amid Growing “No” to Off-Year Revisions
December 2, 2024
- DPP Confirms Plan to Urge 4 Ministers to Scrap Off-Year Price Revisions
November 28, 2024
- 3 Parties Reach Deal on Economic Plan, Off-Year “Abolition” Not Spelled Out
November 21, 2024
- DPP Leader Poised to Urge 4 Ministers to Abolish Off-Year Revisions
November 20, 2024
- DPP Prods Ruling Camp to Be More Specific on Off-Year Revision in Economic Plan
November 19, 2024
- LDP Broadly OKs Draft Economic Package, Adds Text on FY2025 Revision
November 15, 2024
- Draft Economic Package Embraces Measures to Ensure Stable Generic Supply
November 13, 2024
- MHLW Eyes Extra Budget for Pharma Innovation, Generic Rejig
November 11, 2024
REGULATORY
- MHLW Panel OKs List of “High-Priority” Vaccines, including Norovirus Jabs
March 14, 2025
- JPA Asks for Price Penalty for High-Cost Meds with Packaging Unaligned to Dosing
March 14, 2025
- Chuikyo to Discuss Potential Pricing Steps to Deal with Higher Costs of Japan-Made APIs
March 13, 2025
- MHLW to Extend NIP Period for MR Vaccines by 2 Years amid Shortage
March 13, 2025
- Chuikyo Rep Calls for Proper Use of Zepbound, Frets Expansion of Obesity Market
March 13, 2025
1. Build a Strong Employer BrandFirst up, let’s talk about your employer brand. Think of it as your company’s personality and reputation. In Japan’s competitive pharmaceutical and medical device industry, it’s crucial to stand out. You need to showcase your…
A Japanese health ministry panel on December 26 wrapped up its discussions on the next amendment of the Pharmaceuticals and…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…